Remember that record biotech IPO party in 2018? There was no ‘happily ever after’
08 May 2023
IPOAcquisition
Back in the summer of 2018, Aptinyx
$APTX
was budding with high hopes. Its predecessor company, Naurex, had sold to Allergan so Brent Saunders and his crew could advance their “breakthrough” NMDA drug to what looked like a promising drug worth $560 million. Aptinyx would take the rest forward through the clinic.
But over the last five years, that drug and everything that went to Aptinyx went up in multiple blasts of bad data, destroyed by a litany of setbacks and failures that would wipe out all evidence of its former promise. Allergan later would sell to AbbVie, primarily for its Botox franchise, after taking some nasty pipeline hits.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.